Trial Using Motivational Interviewing Positive Affect and Self-Affirmation in Hy

在患有未控制高血压的黑人中，这项随机对照试验将评估一种 将积极情感和自我肯定与激励性访谈相结合的行为干预 血压控制与患者教育/行为契约对照组的比较。本研究 激励性访谈、积极情绪和自我肯定在高血压患者中的应用 (Triumph)建立在NHLBI资助的Carla Boutin Foster博士和 格本加·奥格德贝。凯旋建立在社会认知理论的基础上，运用积极的情感和自我信息 诱导和激励性访谈作为行为策略。凯旋专注于 高血压，因为它是黑人死亡率过高的最常见原因，占更多 比艾滋病毒、糖尿病和凶杀案少活几年。主要目的是评估一项干预措施是否 将积极的情感和自我肯定与激励性访谈相结合可以改善血压 在12个月时与教育/行为合同干预进行比较。次要目标是 1)评估凯旋糖浆对患者内部收缩压(SBP)和住院患者的影响 改变舒张压(DBF)和2)评估凯旋糖浆对住院患者的影响 服药依从性的自我效能感改变。这将是一项在 220名患者从哈莱姆区中心的文艺复兴健康网络招募。主要的结果是血液 压力控制率为12个月。血压(BP)将使用有效的自动数字BP进行评估 监护仪(BPTru)遵循美国心脏协会的指南。患者将被归类为 如果他们的平均BP达到第七届全国检测联合委员会的要求， 高血压患者SBP&lt；130和DBP&lt；80 mm Hg标准的评价和治疗 糖尿病或慢性肾脏疾病)；或SBP&lt；140和DBP&lt；90毫米汞柱(适用于所有其他患者)。布丁博士- 福斯特(PI)召集了生物统计学和流行病学方面的专家作为联合调查员，其中包括Dr。 奥格德贝是行为高血压专家。凯旋将解决一个主要的公共卫生威胁 哈莱姆区中心，三分之一的居民生活在贫困中，超过50%的居民高血压得不到控制 并为将行为科学的基本理论转化为社区干预提供了一个模型。

Among blacks with uncontrolled hypertension, this randomized controlled trial will evaluate the impact of a behavioral intervention that combines positive affect and self-affirmation with motivational interviewing on blood pressure control in comparison to a patient education/behavioral contract control group. This study ntitled Trial Using Motivational Interviewing Positive Affect and Self-Affirmation in Hypertension (TRIUMPH) builds upon a preliminary NHLBI funded study conducted by Drs. Carla Boutin Foster and Gbenga Ogedegbe. TRIUMPH is framed upon Social Cognitive Theory and applies positive affect and selfaffirmation induction and motivational interviewing as behavioral strategies. TRIUMPH focuses on hypertension because it is the single most common cause of excess mortality in blacks, accounting for more years of life lost than HIV, diabetes, and homicide. The primary aim is to evaluate whether an intervention that combines positive affect and self-affirmation with motivational interviewing improves blood pressure control compared to an educational/behavioral contract intervention at 12 months. The secondary aims are 1) to evaluate the impact of TRIUMPH on within-patient change in systolic blood pressure (SBP) and withinpatient change diastolic blood pressure (DBF) and 2) to evaluate the impact of TRIUMPH on within-patient change in self-efficacy for medication adherence. This will be a randomized controlled trial conducted among 220 patients recruited from Renaissance Health Network in Central Harlem. The primary outcome is blood pressure control rate at 12 months. Blood pressure(BP) will be assessed with a valid automated digital BP monitor (BPTru) following American Heart Association guidelines. Patients will be categorized as having controlled BP if they have an average BP that fulfills the Seventh Joint National Committee on Detection, Evaluation and Treatment of Hypertension criteria of SBP < 130 and DBP < 80 mmHg ( for patients with diabetes or chronic kidney disease); or SBP < 140 and DBP < 90 mmHg (for all other patients). Dr. Boutin- Foster (PI) has assembled experts in biostatistics and epidemiology as co-investigators, including Dr. Ogedegbe a behavioral hypertension specialist. TRIUMPH will address a major public health threat in Central Harlem, where 1 in 3 residents live in poverty and more than 50% have uncontrolled hypertension and provide a model for translating basic behavioral science theories to community interventions.